Plain English Summary
Current plain English summary as of 08/04/2020:
Background and study aims
Patients admitted with a hip fracture are typically elderly, frail and have multiple medical co-morbidities, including low red bold cell count (anaemia). As a consequence of the fracture and urgent surgery, patients sustain blood loss, worsening this pre-existing anaemia. In patients with a fractured hip allogenic (blood from a donor) blood transfusion is required in up to 30% of patients. Blood transfusions impose some risks to patients, such as an increased rate of infection. Allogenic blood use is associated with transfusion reactions and an increased length of hospital stay. Concerns regarding patient safety and the costs of allogenic blood have driven efforts to reduce transfusion rates. ‘Intraoperative cell salvage and autotransfusion’ is a method of collecting blood lost during surgery and transfusing it back to the patient. The cell salvage device separates oxygen-carrying red blood cells lost during surgery, prior to transfusing them back to the patient. Complications as a result of cell salvage are rare. Despite not currently being used routinely, there are large potential benefits of using cell salvage during hip fracture surgery. The study aim is to evaluate the clinical effectiveness of cell salvage in hip fracture surgery.
Who can participate?
Participants of 60 years of age and older who have sustained a fracture of the hip who, in the
opinion of the operating surgeon, would benefit from surgery
What does the study involve?
The study will include a comparison between ‘cell salvage’ with ‘treatment as usual’ to the blood lost during hip surgery. Treatment as usual involves a standard suction system removing blood lost in the operation and disposed of in clinical waste. In either treatment arm patients may receive donor’s blood transfusion before the operation. Then need for allogenic blood products will be determined on an individual patient basis, following each centres blood transfusion policy.
What are the possible benefits and risks of participating?
Any operation for a broken hip carries some risks. The risk of surgery with an implant include: bleeding requiring blood transfusion, infection, further fracture, dislocation, leg length discrepancy, blood clots, damage to nerves and blood vessels in the surgical care, and the risks associated with the anaesthetic. Allogenic blood transfusion carries the risk of increased rate of local and systematic infections. These risks are the same as for patients who are not part of this research project. Cell salvage is very safe as patients own blood is used. There is no specific advantage for participant taking part in the trials. However, the information we get from this trial will inform the future practice and will benefit future patients.
Where is the study run from?
John Radcliffe Hospital, Oxford, UK
When is the study starting and how long is it expected to run for?
October 2019 to March 2023
Who is funding the study?
National Institute for Health Research (NIHR)
Who is the main contact?
Katy Mironov
White9@ndorms.ox.ac.uk
_____
Previous plain English summary:
Background and study aims
Patients admitted with a hip fracture are typically elderly, frail and have multiple medical co-morbidities, including low red bold cell count (anaemia). As a consequence of the fracture and urgent surgery, patients sustain blood loss, worsening this pre-existing anaemia. In patients with a fractured hip allogenic (blood from a donor) blood transfusion is required in up to 30% of patients. Blood transfusions impose some risks to patients, such as an increased rate of infection. Allogenic blood use is associated with transfusion reactions and an increased length of hospital stay. Concerns regarding patient safety and the costs of allogenic blood have driven efforts to reduce transfusion rates. ‘Intraoperative cell salvage and autotransfusion’ is a method of collecting blood lost during surgery and transfusing it back to the patient. The cell salvage device separates oxygen-carrying red blood cells lost during surgery, prior to transfusing them back to the patient. Complications as a result of cell salvage are rare. Despite not currently being used routinely, there are large potential benefits of using cell salvage during hip fracture surgery.
The study aim is to evaluate the clinical effectiveness of cell salvage in hip fracture surgery. Prior to assessing this in a full-size clinical trial we need to understand if surgeons and patients are willing to participate in such a study and if sufficient blood is lost during surgery to make cell salvage viable. Therefore this is a feasibility study to determine if a full study is possible and worthwhile.
Who can participate?
Participants of 60 years of age and older who have sustained a fracture of the hip who, in the opinion of the operating surgeon, would benefit from surgery
What does the study involve?
The study will include a comparison between ‘cell salvage and autotransfusion’ with ‘treatment as usual’ to the blood lost during hip surgery. Treatment as usual involves a standard suction system removing blood lost in the operation and disposed of in clinical waste. In either treatment arm patients may receive donor’s blood transfusion before the operation. Then need for allogenic blood products will be determined on an individual patient basis, following each centres blood transfusion policy.
What are the possible benefits and risks of participating?
Any operation for a broken hip carries some risks. The risk of surgery with an implant include: bleeding requiring blood transfusion, infection, further fracture, dislocation, leg length discrepancy, blood clots, damage to nerves and blood vessels in the surgical care, and the risks associated with the anaesthetic. Allogenic blood transfusion carries the risk of increased rate of local and systematic infections. These risks are the same as for patients who are not part of this research project. Cell salvage is very safe as patients own blood is used. There is no specific advantage for participant taking part in the trials. However, the information we get from this trial will inform the future practice and will benefit future patients.
Where is the study run from?
John Radcliffe Hospital, Oxford, UK
When is the study starting and how long is it expected to run for?
October 2019 to September 2020
Who is funding the study?
National Institute for Health Research (NIHR)
Who is the main contact?
Katy Mironov
White9@ndorms.ox.ac.uk
Trial website
Contact information
Type
Scientific
Primary contact
Mrs Katy Mironov
ORCID ID
Contact details
Oxford Trauma Kadoorie Centre Level 3
John Radcliffe Hospital
Headley Way
Oxford
OX3 9DU
United Kingdom
+44 (0)1865 227226
White9@ndorms.ox.ac.uk
Additional identifiers
EudraCT number
Nil known
ClinicalTrials.gov number
Nil known
Protocol/serial number
CPMS 42503
Study information
Scientific title
The World Hip Trauma Evaluation Nine (WHiTE 9) BeST: A multi-centre randomised controlled trial comparing intraoperative cell salvage with standard care in the treatment of hip fractures
Acronym
WHiTE 9 BeST
Study hypothesis
The aim of the main study is to determine the clinical and cost-effectiveness of intraoperative cell salvage, compared to standard care, in improving health-related quality-of-life in patients undergoing hip fracture surgery.
Ethics approval
1. Approved 14/08/2019, Wales Research Ethics Committee 5 (Health and Care Research Wales, Castlebridge 4, 15-19 Cowbridge Road East, Cardiff, CF11 9AB; +447970422139; Wales.REC5@wales.nhs.uk), ref: 19/WA/0197
2. Amendment 02 for the main study approved by Wales Research Ethics Committee 5 on 03/04/2020 (details as above)
Study design
Randomised; Interventional; Design type: Treatment, Surgery
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Hospitals
Trial type
Treatment
Patient information sheet
Not available in web format, please use the contact details to request a patient information sheet
Condition
Fracture of neck of femur
Intervention
Current interventions as of 08/04/2020:
Patients over 60 years of age, both those with and without capacity, who sustain a hip fracture and are treated operatively, will be potentially eligible to be randomised to either undergo cell salvage or they will follow the standard care pathway- a standard suction system removes blood lost in the operating field and it is disposed of in the clinical waste.
In either treatment arm, patients may receive donor's (allogenic) blood transfusion before the operation. The need for allogenic blood products will be determined on an individual patient basis, following each centre's blood transfusion policy.
Patients who are younger than 60, treated non-operatively or undergoing cannulated hip screw fixation will not be eligible. Patients for whom the treating surgeon has already elected to use cell salvage (for example Jehovah Witness) or those who have sustained a pathological fracture will also be excluded.
Participants will undergo surgery at the next available opportunity on a planned trauma list. Participants will be blinded to the treatment allocation. The operating surgeon cannot be blinded to the allocation but they will not be involved in the assessment of outcomes. Participants will be kept blinded until the completion of the trial when the blinding will be broken if requested by the patients. There will be no formal analysis of the success of the blinding.
Following hip surgery, all patients will undergo a routine rehabilitation prior to discharge from the hospital. Research staff will complete the data regarding the operation received and autotransfusion blood volume will be recorded at baseline. In addition, the following data will be
collected:
- Demographic and baseline characteristics (e.g. age, gender, pre-fracture mobility)
- Pre-injury quality of life (EQ5D) and at 4 and 12 months postoperatively
- Routine 'operation notes', perioperative complications, and discharge details
- The volume of blood that was autotransfused, when this was possible
- The number of donor blood units transfused and the date of transfusion will be collected
- Haemoglobin concentration
- Pre and postoperative delirium assessment
- Details of admission, assessment and treatment
- Contact details, including of carers when appropriate
- Complications and SAEs during the study period
Following their 12 months questionnaire, patients will have completed their participation in the trial and will continue to be treated as per normal standard of care.
_____
Previous interventions:
This will be a multi-centre feasibility randomised controlled trial. The study will include a comparison between a cell salvage and autotransfusion with the standard of care approach to the blood lost during hip surgery. The study will be linked to the established WHiTE Comprehensive Cohort Study.
Patients over 60 years of age, both those with and without capacity, who sustain a hip fracture and are treated operatively, will be potentially eligible to be randomised to either undergo cell salvage and autotransfusion or they will follow the standard care pathway- a standard suction system removes blood lost in the operating field and it is disposed of in clinical waste.
In either treatment arm, patients may receive donor's (allogenic) blood transfusion before the operation. The need for allogenic blood products will be determined on an individual patient basis, following each centre's blood transfusion policy.
Patients who are younger than 60, treated non-operatively or undergoing cannulated hip screw fixation will not be eligible. Patients for whom the treating surgeon has already elected to use cell salvage (for example Jehovah Witness) or those who have sustained a pathological fracture will also be excluded.
Participants will undergo surgery at the next available opportunity on a planned trauma list. Participants will be blinded to the treatment allocation. The operating surgeon cannot be blinded to the allocation but they will not be involved in the assessment of outcomes. Participants will be kept blinded until the completion of the trial when the blinding will be broken if requested by the patients. There will be no formal analysis of the success of the blinding.
Following hip surgery, all patients will undergo a routine rehabilitation prior to discharge from the hospital. Research staff will complete the data regarding the operation received and autotransfusion blood volume will be recorded at baseline. In addition, the following data will be collected:
- Demographic and baseline characteristics (e.g. age, gender, pre-fracture mobility)
Pre-injury quality of life (EQ5D) and at 30 and 120 days postoperatively
- Routine 'operation notes', perioperative complications, and discharge details
- The volume of blood that was autotransfused, when this was possible
- The number of donor blood units transfused and the date of transfusion will be collected
- Haemoglobin concentration
- Pre and postoperative delirium assessment
- Details of admission, assessment and treatment
- Contact details, including of carers when appropriate
- Complications and SAEs during the study period
Following their 120-day questionnaire, patients will have completed their participation in the trial and will continue to be treated as per normal standard of care.
Intervention type
Procedure/Surgery
Phase
Drug names
Primary outcome measure
Current primary outcome measure as of 08/04/2020:
Health-related quality of life measured using the EuroQol 5 dimension(EQ-5D-5L) score at baseline (retrospective pre-fracture status) and 4 months post-operatively
_____
Previous primary outcome measure:
1. Recruitment rate per centre
2. The number of patients for whom autotransfusion is possible
3. The volume of blood autotransfused
Secondary outcome measures
Current secondary outcome measures as of 08/04/2020:
1. Health-related quality of life measured using the EuroQol 5 dimension(EQ-5D-5L) score at baseline and 12 months post-operatively
2. Post-operative delirium risk measured using 4AT at baseline
3. Residential status measured using NHFD questions at 4 and 12 months post-surgery
4. Mobility measured using NHFD questions at 4 and 12 months post-surgery
5. Allogenic blood usage measured using hospital records at baseline
6. Mortality measured using death notifications from hospital records at 4 and 12 months post-operatively
7. Haemoglobin concentration at baseline
8. Complications, measured using medical records (check any complication classified as adverse events on the protocol will be collected from recruitment until the 12 -month time point)
9. Costs and comparative cost-effectiveness measured using hospital records and resource use questionnaire at 4 and 12 months post-operatively
_____
Previous secondary outcome measures:
1. Health-related Quality of life will be collected using the EuroQol 5 dimension(EQ-5D-5L) score. This will be collected at baseline(retrospective pre-fracture status), 30 and 120 days post-operatively.
2. Units of allogenic blood transfused, this information will be collected at baseline.
3. Mortality
4. Haemoglobin concentration, this information will be collected at baseline
5. Complications, any complication classified as adverse events on the protocol will be collected from recruitment until the 4-month time point.
5. Resource use, costs and comparative cost-effectiveness
Overall trial start date
01/04/2019
Overall trial end date
31/03/2023
Reason abandoned (if study stopped)
Eligibility
Participant inclusion criteria
Participants of 60 years of age and older who have sustained a fracture of the hip who, in the opinion of the operating surgeon, would benefit from surgery
Participant type
Patient
Age group
Senior
Gender
Both
Target number of participants
Planned Sample Size: 1,128; UK Sample Size: 1,128
Participant exclusion criteria
1. Patients younger than 60 years of age
2. Patients undergoing percutaneous hip screw fixation
3. Patients who have sustained a pathological fracture
4. Patients for whom the treating surgeon has already elected to use cell salvage (for example Jehovah Witness)
Recruitment start date
01/10/2019
Recruitment end date
30/09/2021
Locations
Countries of recruitment
United Kingdom
Trial participating centre
Walsgrave General Hospital
University Hospitals Coventry & Warwickshire NHS Trust
Clifford Bridge Road
Coventry
CV2 2DX
United Kingdom
Trial participating centre
John Radcliffe Hospital
Headley Way
Oxford
OX3 9DU
United Kingdom
Trial participating centre
Warwick Hospital
Lakin Road
Warwick
CV34 5BW
United Kingdom
Trial participating centre
Royal Berkshire NHS Foundation Trust
Royal Berkshire Hospital
London Road
Reading
RG15AN
United Kingdom
Trial participating centre
Medway Maritime Hospital
Medway NHS Foundation Trust
Windmill Road
Gillingham
ME7 5NY
United Kingdom
Trial participating centre
St George’s Hospital
Blackshaw Road
London
SW17 0QT
United Kingdom
Trial participating centre
Royal Derby Hospital
University Hospitals of Derby and Burton NHS Foundation Trust
Uttoxeter Road
Derby
DE22 3NE
United Kingdom
Trial participating centre
Queen's Medical Centre
Nottingham University Hospitals NHS Trust
Derby Road
Nottingham
NG7 2UH
United Kingdom
Trial participating centre
Whipps Cross Hospital
Leytonstone
London
E11 1NR
United Kingdom
Sponsor information
Organisation
University Hospitals Coventry and Warwickshire NHS Trust
Sponsor details
Walsgrave General Hospital
Clifford Bridge Road
Coventry
CV2 2DX
United Kingdom
+44 (0)2476 965031
R&DSponsorship@uhcw.nhs.uk
Sponsor type
Hospital/treatment centre
Website
Funders
Funder type
Government
Funder name
NIHR Central Commissioning Facility (CCF); Grant Codes: PB-PG-0817-20037
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
Planned publication in a high-impact peer-reviewed journal
IPD sharing statement:
The current data sharing plans for this study are unknown and will be available at a later date
Intention to publish date
31/03/2023
Participant level data
To be made available at a later date
Basic results (scientific)
Publication list